GlaxoSmithKline's CEO on the China Controversy, Transparency, and Big Pharma's Reputation | Forbes
3,380 views · Published 18 October 2013 · 6:47 · Indexed 8 November 2026
Channel: Forbes · 2013 · Science & Technology
Forbes Senior Editor Matthew Herper sits down with Sir Andrew Witty to ask how accusations of bribery have affected the company's reputation, its efforts at releasing clinical trial data, and its malaria vaccine.
More from this channel
-
1:16
Reporter Versus Jet Ski
-
1:03
CEO of Mahindra Satyam, CP Gurnani, About Davos 2011
-
6:58
Clayton Christensen On His Heart Attack
-
2:18
Clayton Christensen on Science and Religion
-
3:34
Clayton Christensen on Disrupting Health Care
-
2:05
Clayton Christensen on Health Care
-
1:27
Clayton Christensen's Oncologist: The Prognosis
-
1:14
Clayton Christensen's Oncologist: The Cost Of Care